Alisertib is the first oral selective AURKA inhibitor with demonstrated clinical efficacy in phase II/III clinical trials for relapsed or refractory peripheral T-cell lymphoma (NCT01482962), ovarian cancer (NCT00853307), and acute myelocytic leukemia (NCT02560025), showing translational potential for HCC. Here, AURKA is linked to peripheral T-cell lymphoma, not otherwise specified.